Effect of angiopoietin-like protein 3 inhibitors on lipid profile and other biomarkers: a meta-analysis of randomized controlled trials
Authors' conclusion
ANGPTL3 inhibition offers broad lipid-lowering benefits, with particularly marked reductions in TG-rich lipoproteins.
Study context
- Population
- Randomized controlled trials (RCTs) of ANGPTL3 inhibitors vs placebo, searched to July 2025
- Participants
- 1,254 participants9 RCTs
- Comparison
- ANGPTL3 inhibitors vs placebo
- Outcome
- Percentage change from baseline in lipids and biomarkers
Methodological detailsfixed- and random-effects models
- Fixed- and random-effects models
Pooled result
As reported in the abstract
- Triglycerides (TG)
- −47.1%
- LDL-C
- −21.6%
- Apolipoprotein B (ApoB)
- −19.9%
- non-HDL-C
- −31.5%
- Total cholesterol (TC)
- −32.8%
- Very-low-density lipoprotein cholesterol (VLDL-C)
- −40.6%
- Remnant cholesterol (RC)
- −72.7%
- Lp(a)
- −11.5%
- Apolipoprotein A1 (ApoA1)
- −18.3%
- ApoE
- −16.4%
- Circulating ANGPTL3 protein
- −70.7%
Further pooled results
By mechanism of action (subgroup)
- Greater reductions in LDL-C, ApoB, non-HDL-C and TC with evinacumab vs other groups
- More pronounced VLDL-C lowering with small interfering RNAs (siRNAs) vs vupanorsen
Original publication
Effect of angiopoietin-like protein 3 inhibitors on lipid profile and other biomarkers: a meta-analysis of randomized controlled trials. Eur J Prev Cardiol. Published 22 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →